




VIFOR PHARMA OCTAVIAN SEMINAR 2021

14 JANUARY 2021


STRONG TRACK RECORD NET SALES AND EBITDA GROWTH







IN CHF MILLION







"

In 2020, net sales are expected to grow in the range of 5% at constant exchange rates, reported EBITDA is expected to grow in the range of 20%.

1) Subject to no worsening of the situation due to COVID-19; full-year 2019 net sales and EBITDA excluding OM Pharma of CHF 1'725m and CHF 485m, respectively

STRONG TRACK RECORD KEY ACHIEVEMENTS IN 2020




CLINICAL TRIALS	 AFFIRM-AHF study of Ferinject[®] positive readout KALM-2 phase-III study of Korsuva[™] positive readout INNO₂VATE phase-III study of vadadustat positive readout Recruitment in the phase-II study of VIT-2763 in beta-thalassemia started 	✓ ✓ ✓
MARKET ACCESS	 Ferinject[®] launched in Japan China: Ferinject[®] and Veltassa[®] partnered & NDA submission for Ferinject[®] accepted Avacopan filing accepted for review in Europe Korsuva[™] filed in the US 	✓ ✓ ✓
BUSINESS DEVELOPMENT	 In-licensing agreement with Cara Therapeutics for Korsuva[™] extended Worldwide rights¹ of ANG-3777 licensed from Angion Biomedica Divestment of OM Pharma strengthens focus on key therapeutic areas 	\checkmark

1) Excluding China, Taiwan, Hong Kong and Macau; for all nephrology indications and congestive heart-failure

LEADING PORTFOLIO IN TARGET THERAPY AREAS






1) Restriction of iron availability, i.e. for treating non-transfusion-dependent thalassemia or sickle cell disease 2) In-licensed products


VIFOR PHARMA STRATEGIC FOCUS THREE AREAS AS BASIS FOR FUTURE GROWTH





IRON DEFICIENCY – MARKET OVERVIEW DRIVING OVERALL MARKET GROWTH






Ferinject[®]/Injectafer[®], Venofer[®] and Maltofer[®]

Source: quarterly IQVIA[™] MIDAS[®] panel, GERS, Insight Health, DLI, moving annual total Q3-2020. Average 2019 exchange rates have been applied

IRON DEFICIENCY – FERINJECT® INDICATIONS INDICATIONS SPLIT DRIVEN BY REGIONAL FOCUS






1) Pre-COVID-19 year-over-year growth rate as per end of Q1 2020 Source: quarterly IQVIA[™] MIDAS[®] panel, GERS, Insight Health, moving annual total Q2 2019-20 in 100mg equivalents; EU5: Germany, France, Italy, Spain and the United Kingdom

IRON DEFICIENCY – FERINJECT® PBM¹ EUROPE MAJOR GROWTH OPPORTUNITY







- PBM strongly supported by World Health Organization
- Estimated savings per patient of CHF 850 vs usual care²
- Additional real world evidence data expected in 2021

IRON DEFICIENCY – FERINJECT® MOLECULE NANOMEDICINES – LARGE AND COMPLEX STRUCTURE






NANOMEDICINES


- Ferinject[®] and Venofer[®] are nanomedicines
- These are large and complex molecules, defined by their manufacturing processes
- Any potential copy of a nanomedicine will inevitably have small differences
- Scientific evidence shows that small changes can lead to clinically meaningful differences¹
- US & EU: specific regulatory requirements

1) Rottembourg et al. Nephrol Dial Transplant 2011; 26: 3262–3267, M.L. Aguera, A. Martin-Malo, M.A. Alvares de Lara et al. Nefrologia 2014;34(S1), abstr 319

VIFOR PHARMA STRATEGIC FOCUS THREE AREAS AS BASIS FOR FUTURE GROWTH



VIFOR HARMA



NEPHROLOGY OPPORTUNITIES LARGE AND GROWING MARKET WITH HIGH UNMET MEDICAL NEED



COMMERCIAL PIPELINE **BD&L OPPORTUNITIES Uremic pruritus** CKD progression drivers Iron deficiency ANCA associated vasculitis CKD associated complications Anaemia Secondary hyperparathyroidism Diabetic kidney disease Dialysis related complications Cardiac surgery associated acute kidney injury Hyperphosphatemia Acute kidney injury **Delayed graft function** Hyperkalemia C3G Transplantation

NEPHROLOGY – PARTNERSHIP WITH FMC¹ UNIQUE EXPERTISE AND PATIENT ACCESS





STRONG IRON AND PHARMA EXPERTISE

- Clinical development
- Manufacturing, regulatory and market access experiences
- Global commercial presence



GLOBAL LEADER IN DIALYSIS



>52 million dialysis treatments p.a.

n >4'000 nts p.a. clinics





F



45% Stake




Global leadership in nephrology through:

- Combination of strengths
- Optimal sourcing of innovation
- Access to patient data & faster clinical trial execution
- Improving outcomes via treatment algorithms

1) Fresenius Medical Care


VIFOR PHARMA STRATEGIC FOCUS THREE AREAS AS BASIS FOR FUTURE GROWTH





CARDIO-RENAL – PATIENT POPULATIONNATURAL EXTENSION OF OUR THERAPY AREA FOCUS






ALREADY TARGETED TODAY

CARDIO-RENAL – FERINJECT® EUROPE SIGNIFICANT GROWTH MOMENTUM

IN-MARKET SALES IN HEART FAILURE – EU5




VIFOR PHARMA

- ESC guideline recommendation since 2016
- Leverage strong clinical data
- ESC guideline update expected in 2021
- Market opportunity over CHF 450m

EU5: Germany, France, Italy, Spain and the United Kingdom ESC = European Society of Cardiology Source: IQVIA[™] hospital ward data, NVI, Pharmafakt, DN sales, Farma&Cia, APDD, Q2-2020

CARDIO-RENAL – INJECTAFER® US MAJOR UNADDRESSED GROWTH OPPORTUNITY





- Injectafer[®] label extension based on FAIR-HF & AFFIRM-AHF in 2021/22
- US guideline update in 2022
- Further label and guideline strengthening following HEART-FID study in 2023/24
- US market opportunity over USD 1 billion


Source: interviews with US HF specialists, ZS analysis on claims, ATU research, scientific papers

¹⁾ Heart failure with preserved injection fraction

CARDIO-RENAL – VELTASSA® SIGNIFICANT OPPORTUNITY WITH EXISTING PRESCRIBERS



IN-MARKET SALES



KEY CHARACTERISTICS

- Calcium-based, non-absorbed
- 52-weeks data available
- Acute & chronic usage

KEY FOCUS

- Build awareness
- Establish clinical differentiation
- Improve pull-through
- DIAMOND study is significant growth accelerator and "differentiator"

[■] Veltassa[®] ■ Sodium zirconium cyclosilicate ■ Other potassium binders

Source: monthly IQVIA[™] MIDAS[®] panel, GERS, InsightHealth, DLI, moving annual total Q3-2020. Average 2019 exchange rates have been applied.

PROVEN BD&L CAPABILITIES & STRONG PIPELINE KEY UPCOMING LAUNCHES AND DATA READOUTS



PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3	PRE-COMMERCIAL	LIFE CYCLE MANAGEMENT
NephThera (Kidney fibrosis)		VIT-2763 (Ferroportin inhibitor) ANG-3777 ¹ (CSA-AKI)	ANG-37771 (DGF)	Rayaldee®1 Korsuva™1 Avacopan ¹ Vadadustat ¹	<image/> <image/> <image/> <image/>

BD&L = Business development and licensing 1) In-licensed products DGF = Delayed graft function CSA-AKI = Cardiac surgery associated acute kidney injury 2) Study conducted by our US partner Daiichi Sankyo

AVACOPAN NEW STANDARD OF CARE IN ANCA-AV



Reduce glucocorticoid toxicity Sustain remission vs. standard of care statistically superior at 52 weeks Avacopan¹ **Global rights Orphan and rare renal disease** excl. US around 50k patients in Europe Launch in Europe in ANCA-AV Potential in further indication end 2021 / early 2022 including C3G and HS

ANCA-AV = Anti-neutrophil cytoplasmic antibody-associated vasculitis 1) In-licensed product C3G = C3 glomerulopathy

HS = Hidradenitis suppurativa

KORSUVA™ (CR845/DIFELIKEFALIN) INJECTION INNOVATION IN CKD-ASSOCIATED PRURITUS

~40% of ESRD patients

moderate to severe CKD-aP

No approved treatment in the US and Europe

Standard of care with poor efficacy

and/or unfavorable safety profile

Korsuva^{™ 1}

CARA

Global rights excl. Japan and South Korea

Launch in the US in end of 2021 followed by Europe in early 2022

1) In-licensed product



Leverage commercial organisation

established presence in dialysis

First small molecule **Global rights**² in DGF and CSA-AKI hepatocyte growth factor mimetic **ANG-3777**¹ ~110k patients with CSA-AKI ~15k patients with DGF US and EU5 combined US and EU5 combined angion Phase-II study in CSA-AKI Phase-III study in DGF read out in Q2 2021 read out in end of 2021

EXPANDING LEADERSHIP ON THE NEPHROLOGY CHAIN

DGF = Delayed graft function 1) In-licensed product

ANG-3777

CSA-AKI = Cardiac surgery associated acute kidney injury 2) Excluding China, Taiwan, Hong Kong and Macau

14 JANUARY 2021






VIT-2763 (FERROPORTIN INHIBITOR) TARGETING RARE BLOOD DISORDERS





Oral small molecule



Blocks iron transport to the blood



Mechanism similar to hepcidin

BETA THALASSEMIA

SICKLE CELL DISEASE

Unmet need

Transfusion burden and iron overload

Addressable patients¹

Approx. 25'000

Expected completion in H2 2021

Pain crisis and and organ damage

Approx. 150'000

Study initiation expected in 2021

1) US and EU combined estimate

Phase-II status





	 Ferinject[®] approval in China 		
	■ Korsuva TM launch in the US & approval in Europe		
MARKET ACCESS	 Avacopan approval in Europe 		
	■ Avacopan & Korsuva [™] partnering in China		
	 Vadadustat filing in the US by our partner Akebia Therapeutics, Inc. 		
	VIT-2763 phase-II readout in beta thalassemia in H2 2021		
CLINICAL TRIALS	ANG-3777 phase-II readout in CSA-AKI in Q2 2021		
	ANG-3777 phase-III readout in DGF in Q4 2021		
BD&L	At least two in-licensing deals, product acquisition or corporate transactions		

KEY INVESTMENT HIGHLIGHTS



- Strong track record of profitable growth and resilient cash flow generation
 - Global leadership in growing iron deficiency & iron deficiency anaemia markets
 - Global leadership in nephrology empowered by unique FMC¹ partnership



- Proven BD&L capabilities and "partner of choice" in nephrology
- Positioned to unlock attractive high-growth opportunities in cardio-renal area
- Delivering material pipeline and international expansion opportunities
- Highly experienced leadership team

1) Fresenius Medical Care

CONTACT INFORMATION





Colin Bond Chief Financial Officer

Phone: +41 58 851 83 53 Email: <u>colin.bond@viforpharma.com</u>



Julien Vignot Head of Investor Relations

Phone: +41 58 851 66 90 Email: julien.vignot@viforpharma.com

Investor relations



Laurent de Weck Investor Relations Senior Manager

Phone: +41 58 851 80 95 Email: <u>laurent.deweck@viforpharma.com</u>





Certain statements, beliefs and opinions in this presentation are forward-looking, which reflect the Company's or, as appropriate, the Company's directors' current expectations and projections about future events. By their nature, forwardlooking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this presentation as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its of their parent or subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this presentation or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this presentation.